Change Agents Corporation: High-Cost ELOC Financing and $110.4 Million Deficit Accelerate Solvency Risks Near New Jersey Hub as Segment Revenues Hold at Zero
Date : 2026-08-12
Reading : 188
HDIN Executive Takeaways
1. Change Agents Corporation [NASDAQ: CHGA] filed an S-1 registration statement covering 35,569,258 resale common shares, securing $0 in direct proceeds while relying on a $10.0 million Hudson Global Ventures ELOC line at $0.30 per share.
2. With $200,000 in cash as of July 31, 2026, against a $416,667 monthly burn rate, autonomous operational runway is restricted to under 15 days, creating critical going concern exposure.
3. Mandatory cash debt amortizations of $148,500 per month and Series F preferred redemptions of $125,000 per month will consume projected ELOC draws, starving newly formed software and defense segments of expansion capital.
Figure Change Agents Corp (CHGA): S-1 Forensic Audit & Strategic Pivot Analysis
Financial Mechanics, Segmental Operations, and Capital Structure
An audit of the S-1 registration statement for Change Agents Corporation [NASDAQ: CHGA] (formerly Avalon GloboCare Corp.) confirms that net revenues from continuing operations stood at $0 across the fiscal years ended December 31, 2024, and December 31, 2025, as well as the three-month periods ended March 31, 2025, and March 31, 2026. The entity carries an accumulated deficit of $110,413,796 as of March 31, 2026, triggering a formal going concern explanatory paragraph from independent auditor M&K CPAS, PLLC.
As of July 31, 2026, Change Agents Corporation held $200,000 in total cash against an estimated twelve-month forward operational cash requirement of $5,000,000 ($416,667 per month), establishing an unfunded twelve-month capital gap of $4,800,000 and an autonomous operational runway of under 15 days.
The company's tangible net asset backing is negative. Net Tangible Book Value (NTBV) deficit stood at -$5,736,256 (-$1.182 per share across 4,854,009 common shares) as of December 31, 2025, and -$2,697,344 (-$0.324 per share across 8,323,609 common shares) as of March 31, 2026. This deficit persists despite stockholders' equity of $11,724,057 at March 31, 2026, because assets are dominated by $12,808,197 in goodwill and $1,613,204 in net intangible assets ($2,158,167 as of December 31, 2025) resulting from the December 2025 acquisition of RPM Interactive, Inc. Intangible paper valuations total $14,421,401. Immediate dilution per share for new investors purchasing at the fixed $0.30 Equity Line of Credit (ELOC) price is $0.624 per share against the March 31, 2026 NTBV, and $0.824 per share (164.8% of purchase price) against a hypothetical $0.50 secondary market price.
Working capital deficit progressed from -$12,651,237 (Current Assets of $1,495,877 vs. Current Liabilities of $14,147,114) as of December 31, 2025, to -$2,774,431 (Current Assets of $1,670,142 vs. Current Liabilities of $4,444,573) as of March 31, 2026. The $9,876,806 (78.1%) improvement in working capital deficit was driven by the sale of subsidiary Avalon RT 9 Properties LLC (removing $6,061,077 in current liabilities of discontinued operations), the conversion of $545,950 in June 2024 Convertible Notes into common stock, and a $526,000 reduction in accrued professional fees. Accrued liabilities backlog as of March 31, 2026, includes $1,306,913 in unpaid professional fees and $718,595 in accrued payroll and compensation ($2,025,508 aggregate).
Table Historical Financial Performance and Operating Cash Flow Analysis
Operating expenses across continuing operations expand due to transaction advisory and legal fees associated with acquisitions and corporate restructurings.
Table Continuing Operating Expenses Breakdown and Cost Structure Analysis
The capitalization structure comprises 110,000,000 authorized shares (100,000,000 common stock, par value $0.0001; 10,000,000 preferred stock, par value $0.0001). As of August 7, 2026, issued and outstanding common shares totaled 19,646,803.
Table Preferred Equity, Warrant, and Stock Option Capital Structure Overview
Total warrant overhang stands at 15,199,384 shares with a weighted average exercise price of $0.51 per share, representing 77.4% of pre-offering common stock.
The active debt portfolio totals $2.1 million as of July 31, 2026, comprising short-term, high-cost debt instruments featuring Original Issue Discount (OID) structures and weekly/monthly amortization schedules.
Table Outstanding Debt Obligations and Convertible Financing Structure
Supply Chain Footprint, Contractual Exposure, and Legal Liabilities
Change Agents Corporation maintains its principal executive headquarters at 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728. The building was previously owned by subsidiary Avalon RT 9 Properties LLC, which generated rental revenues of $1,410,259 in FY 2025 ($1,333,403 in FY 2024) at a 98.5% occupancy rate. On February 18, 2026, Change Agents Corporation sold 100% of Avalon RT 9 to Chairman Wenzhao "Daniel" Lu for $9,000,000 (satisfying $3,158,078 in historical cash advances and assuming $5,900,000 in mortgage debt, exceeding a CBRE appraisal of $8,700,000). The transaction generated a net deconsolidation gain of $1,861,266, which was credited directly to Additional Paid-in Capital (APIC) under SEC related-party rules rather than recognized as income. Change Agents Corporation subsequently leased back its headquarters office space from Mr. Lu.
Total undiscounted operating lease liabilities stand at $178,500 ($97,000 due twelve months ending March 31, 2027; $70,500 due twelve months ending March 31, 2028; $11,000 due twelve months ending March 31, 2029). Discounted present value is $160,345 utilizing a 12.0% discount rate ($83,508 current portion; $76,837 non-current portion).
The consumer health technology segment (Keto Air breathalyzer measuring breath acetone PPM across tiers: 0–3.99 Inadequate, 4–9.99 Mild, 10–40 Optimal, >40 Alarming) operates via an exclusive North American distribution contract with Qi Diagnostics executed in 2024. Formal contractual exclusivity expired in July 2025, though Change Agents Corporation remains the sole distributor in North America. The segment owns zero manufacturing facilities and relies on a single Hong Kong technology group to produce all device hardware. Inventory of Keto Air finished goods was $71,862 as of March 31, 2026 ($74,841 as of December 31, 2025). Commercial distribution uses direct website channels, influencer partnerships, and a wellness contract with the Law Enforcement Association of America (LEAA). Development of a companion THC breathalyzer was permanently discontinued in March 2026 due to lack of capital.
The software segment (Avalon Quantum AI LLC) operates the Catch-Up short-form video platform and The Beacon Agentic GEO search app. Catch-Up Phase 1 targeted podcasters; Phase 2 (scheduled launch Q3 2026) expands to social media influencers, product marketers, and e-commerce. On March 31, 2026, the company engaged Caylent, Inc. (an AWS Premier Tier Consulting Partner) to build and manage its cloud backend on Amazon Web Services (AWS). Change Agents Corporation capitalized $18,037 in internal-use software development costs during Q1 2026 under ASC 350-40. On August 4, 2026, the company announced the formation of Autonomous Air Defense Systems LLC, a wholly-owned subsidiary tasked with developing generative AI models for counter-unmanned aerial systems (C-UAS) and autonomous drone surveillance, appointing Major General (Ret.) Malcolm Frost to its advisory board.
Active operations in China (Avalon Shanghai) were wound down between 2022 and 2023. Chinese cash balances were liquidated to $78 (0.01% of total cash) as of March 31, 2026 ($492 as of December 31, 2025). Foreign currency translation loss in OCI was $9,402 in FY 2025. Legacy cellular therapy patents co-owned with the Massachusetts Institute of Technology (MIT) require MIT's express consent for unilateral licensing or enforcement. Three provisional patent applications have been filed for the Catch-Up platform.
Legal and non-operating liabilities include:
* Nationwide Children's Hospital Settlement: Lawsuit filed October 28, 2019, alleging trade secret misappropriation against Change Agents Corporation and subsidiary Genexosome. Settled June 7, 2022, for $450,000 paid on 60-day, 1-year, and 2-year anniversaries ($363,450 accrued balance remaining as of March 31, 2026). Enforces a profit-sharing liability equal to 30% of the first $3,333,333 in pre-tax profits, 20% of the second $3,333,333, and 10% of the third $3,333,333 (up to $2,000,000 cumulative cash drag from first $10.0M pre-tax profit).
* Laboratory Services MSO, LLC Litigation: Lawsuit filed July 22, 2025, in DE Court of Chancery; settled August 26, 2025, for $1,722,000 ($50,000 legal fees, $22,000 interest). A $1,650,000 write-off taken in Q2 2025 was reinstated in Q3 2025. Following a $600,000 initial payment in August 2025, the remaining $1,122,000 balance is payable in 12 monthly cash installments of $93,500 through August 2026.
* IRS Section 6038 Tax Penalty: $10,000 penalty assessed for failure to file foreign entity tax disclosures (under active appeal).
* Hudson ELOC Warrant Buyout Obligation: Stockholder approval for shares underlying the Hudson Warrant must be obtained within 75 calendar days of July 22, 2026; failure allows Hudson to demand a $250,000 cash buyout to extinguish the warrant. Contract carries open-market "Buy-In" cover liabilities for delayed share delivery.
* Beijing Genexosome Liability: $100,000 in unpaid acquisition consideration from 2017 remains due to related party Dr. Yu Zhou (former director and 40% owner of Genexosome).
* Nasdaq Exchange Deficiency: Written notice received April 15, 2026 under Listing Rule 5550(a)(2) for closing below $1.00 for 30 consecutive business days. Compliance grace period runs through October 12, 2026.
The corporate governance framework features a 4-member Board of Directors (3 independent under Nasdaq rules following the simultaneous resignations of William Stilley, Wilbert Tauzin, and Tevi Troy on February 24, 2026). The board comprises Wenzhao "Daniel" Lu (Chairman, non-independent), Steven A. Sanders (Lead Independent Director, Of Counsel Ortoli Rosenstadt LLP), Lourdes Felix (Audit Chair, CEO/CFO BioCorRx Inc.), and Michael Mathews (Compensation Chair, former CEO Interclick). The executive officer suite consists of Meng Li (Interim CEO & COO), Sam Knipper (CFO, SEC Reporting Manager at Brio Financial Group, appointed June 3, 2026), Luisa Ingargiola (CSO, former CFO), and Michael Mathews (CEO of Avalon Quantum AI LLC). The company operates without a Chief Technology Officer (CTO). Total headcount as of July 31, 2026, is 3 full-time employees and 5 sub-contractors (8 total personnel).
Luisa Ingargiola’s Executive Retention Agreement dated June 3, 2026, sets base salary at $230,000, up to a 100% annual bonus ($230,000), a $230,000 cash bonus upon stockholder approval of the Series E conversion, a $230,000 change-of-control cash bonus, and 12 months salary severance ($230,000) plus option acceleration. Ms. Ingargiola received a $175,000 cash bonus in FY 2025 alongside a $350,000 base salary. Meng Li’s COO contract enforces a 12-month base salary severance clause ($340,000 historical rate). Equity incentive plans include the 2026 Omnibus Plan (2,000,000 shares reserved; 1,200,000 ISO cap), the 2020 Plan (175,537 shares available/outstanding), and the 2019 Plan (6,213 shares available).
Table Insider Ownership and Significant Shareholder Position Analysis
Related-party payments include $385,627 paid cumulatively from 2022 through Q1 2026 ($15,000 Q1 2026; $15,597 Q1 2025; $60,794 FY 2025; $63,644 FY 2024; $446,558 through August 2026) to former director Wilbert Tauzin and his son for consulting services. Chairman Lu previously provided a $20.0 million unsecured credit line at 5% interest (matured December 31, 2024; $42,445 interest paid in FY 2024).
M&K CPAS, PLLC issued an unqualified audit opinion for FY 2025 and FY 2024 with a going concern explanatory paragraph, disclaimed an opinion on Internal Control over Financial Reporting (ICFR), and identified the valuation of Goodwill ($12,808,197) and Intangibles ($2,252,000) from the RPM acquisition as a Critical Audit Matter (CAM). Recent accounting standard adoptions include ASU 2020-06, ASU 2023-07, and ASU 2023-09, while ASU 2024-03/2025-01, ASU 2025-06, ASU 2025-11, and ASU 2025-12 remain under evaluation.
HDIN Institutional Research Verdict
The registered S-1 resale offering functions as a liquidity preservation structure rather than an expansion capital raise. Change Agents Corporation receives $0 in direct proceeds from secondary resales, relying on Hudson Global Ventures drawing down up to $10.0 million under the ELOC at a fixed price of $0.30 per share. Fully drawing the line requires issuing 33,333,333 common shares, expanding the outstanding common stock base from 19,646,803 to 52,980,136 shares (a 169.6% dilution). If all registered resale shares (35,569,258) are issued, common shares reach 53,906,061 (an 181.0% dilution).
The cash flow absorption of existing obligations will consume available capital. Servicing the Agile Lending loan ($148,500 monthly amortization), executing Series F mandatory redemptions ($125,000 monthly starting October 2026), and clearing $2,025,508 in accrued professional and payroll liabilities requires $2,846,508 over the next four months—exceeding the company's $200,000 cash balance and available operating cash flows.
ELOC draws require the stock price to remain above $0.41 per share on the two trading days prior to a Put Date to trigger even the minimum $15,000 draw. With the stock trading below the Nasdaq $1.00 minimum bid threshold (under active deficiency notice through October 12, 2026), continuous market dumping of registered resale shares by Hudson risks driving the market price below the $0.41 floor, which would freeze access to the ELOC and accelerate insolvency.
Presentation Download & Video Access:
- Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
- Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer:
"This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards."
1. Change Agents Corporation [NASDAQ: CHGA] filed an S-1 registration statement covering 35,569,258 resale common shares, securing $0 in direct proceeds while relying on a $10.0 million Hudson Global Ventures ELOC line at $0.30 per share.
2. With $200,000 in cash as of July 31, 2026, against a $416,667 monthly burn rate, autonomous operational runway is restricted to under 15 days, creating critical going concern exposure.
3. Mandatory cash debt amortizations of $148,500 per month and Series F preferred redemptions of $125,000 per month will consume projected ELOC draws, starving newly formed software and defense segments of expansion capital.
Figure Change Agents Corp (CHGA): S-1 Forensic Audit & Strategic Pivot Analysis
Financial Mechanics, Segmental Operations, and Capital StructureAn audit of the S-1 registration statement for Change Agents Corporation [NASDAQ: CHGA] (formerly Avalon GloboCare Corp.) confirms that net revenues from continuing operations stood at $0 across the fiscal years ended December 31, 2024, and December 31, 2025, as well as the three-month periods ended March 31, 2025, and March 31, 2026. The entity carries an accumulated deficit of $110,413,796 as of March 31, 2026, triggering a formal going concern explanatory paragraph from independent auditor M&K CPAS, PLLC.
As of July 31, 2026, Change Agents Corporation held $200,000 in total cash against an estimated twelve-month forward operational cash requirement of $5,000,000 ($416,667 per month), establishing an unfunded twelve-month capital gap of $4,800,000 and an autonomous operational runway of under 15 days.
The company's tangible net asset backing is negative. Net Tangible Book Value (NTBV) deficit stood at -$5,736,256 (-$1.182 per share across 4,854,009 common shares) as of December 31, 2025, and -$2,697,344 (-$0.324 per share across 8,323,609 common shares) as of March 31, 2026. This deficit persists despite stockholders' equity of $11,724,057 at March 31, 2026, because assets are dominated by $12,808,197 in goodwill and $1,613,204 in net intangible assets ($2,158,167 as of December 31, 2025) resulting from the December 2025 acquisition of RPM Interactive, Inc. Intangible paper valuations total $14,421,401. Immediate dilution per share for new investors purchasing at the fixed $0.30 Equity Line of Credit (ELOC) price is $0.624 per share against the March 31, 2026 NTBV, and $0.824 per share (164.8% of purchase price) against a hypothetical $0.50 secondary market price.
Working capital deficit progressed from -$12,651,237 (Current Assets of $1,495,877 vs. Current Liabilities of $14,147,114) as of December 31, 2025, to -$2,774,431 (Current Assets of $1,670,142 vs. Current Liabilities of $4,444,573) as of March 31, 2026. The $9,876,806 (78.1%) improvement in working capital deficit was driven by the sale of subsidiary Avalon RT 9 Properties LLC (removing $6,061,077 in current liabilities of discontinued operations), the conversion of $545,950 in June 2024 Convertible Notes into common stock, and a $526,000 reduction in accrued professional fees. Accrued liabilities backlog as of March 31, 2026, includes $1,306,913 in unpaid professional fees and $718,595 in accrued payroll and compensation ($2,025,508 aggregate).
Table Historical Financial Performance and Operating Cash Flow Analysis
| Historical Financial Performance Metric | FY 2024 ($) | FY 2025 ($) | Q1 2025 ($) | Q1 2026 ($) |
| Revenues from Continuing Operations | 0 | 0 | 0 | 0 |
| Loss from Operations (Continuing) | (4,841,250) | (7,591,359) | (1,785,423) | (2,721,126) |
| Net Loss from Continuing Operations | (7,039,604) | (17,518,873) | (2,266,680) | (4,376,680) |
| Operating Cash Flow Deficit | (4,668,458) | (4,580,620) | N/A | (2,860,379) |
| Monthly Operating Cash Burn | (389,038) | (381,718) | N/A | (953,460) |
| Stock-Based Compensation (SBC) | 521,509 | 1,816,462 | 26,371 | 319,819 |
| Non-GAAP Adjusted EBITDA | (3,435,689) | (6,005,577) | (2,152,764) | (1,838,149) |
Operating expenses across continuing operations expand due to transaction advisory and legal fees associated with acquisitions and corporate restructurings.
Table Continuing Operating Expenses Breakdown and Cost Structure Analysis
| Continuing Operating Expense Item | FY 2024 ($) | FY 2024 Share (%) | FY 2025 ($) | FY 2025 Share (%) | Q1 2026 ($) | Q1 2026 Share (%) |
| Professional Fees | 1,590,268 | 39.81% | 5,254,207 | 65.81% | 1,581,951 | 58.14% |
| Compensation & Benefits | 1,308,854 | 32.76% | 1,101,574 | 13.80% | 223,416 | 8.21% |
| Advertising & Marketing | 237,671 | 5.95% | 843,497 | 10.56% | 209,846 | 7.71% |
| Amortization of Intangibles | 0 | 0.00% | 93,833 | 1.18% | 563,000 | 20.69% |
| Other General & Administrative | 857,869 | 21.48% | 784,758 | 9.83% | 142,913 | 5.25% |
| Total Continuing Operating Expenses | 3,994,662 | 100.00% | 7,984,036 | 100.00% | 2,721,126 | 100.00% |
The capitalization structure comprises 110,000,000 authorized shares (100,000,000 common stock, par value $0.0001; 10,000,000 preferred stock, par value $0.0001). As of August 7, 2026, issued and outstanding common shares totaled 19,646,803.
Table Preferred Equity, Warrant, and Stock Option Capital Structure Overview
| Capital Instrument / Preferred Class | Stated Value / Liquidation ($) | Outstanding Units | Conversion Terms & Common Equivalent | Ranking & Features |
| Series C Preferred Stock | 3,077,000 | 3,077 shares | $2.41/share (~1,276,763 common shares) | Senior to common; 4.99% blocker; non-voting. |
| Series D Preferred Stock | 5,000,000 | 0 shares (5,000 cancelled) | Exchanged May 6, 2026 for 2,074,689 common shares | Exchanged by Chairman Wenzhao Lu; eliminated. |
| Series E Preferred Stock | 19,500,000 | 19,500 shares | $1.50/share (13,000,000 common shares) | RPM Merger; non-voting; 19.99% Nasdaq Cap (889,876 shares max without vote). |
| Series F Preferred Stock | 400,000 | 400 shares | $0.50/share (800,000 common shares) | Issued July 2026; 25% mandatory monthly cash redemptions at 125% premium. |
| Series A & B Preferred | 0 | 0 shares | N/A | Legally eliminated March 7, 2025. |
| Series A-1 Warrants | N/A | 6,372,550 warrants | Exercise price $0.51 per share | Expires 5 years from stockholder approval. |
| Series A-2 Warrants | N/A | 6,372,550 warrants | Exercise price $0.51 per share | Expires 18 months from stockholder approval. |
| Pre-funded Warrants | N/A | 1,125,000 warrants | Exercise price $0.001 per share | Immediately exercisable; no expiration date. |
| ELOC Commitment Warrant | N/A | 925,925 warrants | Exercise price $0.01 per share | Expires 5 years from stockholder approval. |
| Placement Agent Warrants | N/A | 318,628 warrants | Exercise price $0.6375 per share | Issued to H.C. Wainwright; 5-year expiration. |
| Legacy Warrants | N/A | 84,731 warrants | Weighted average exercise price $20.40 | Various legacy expirations. |
| Active Stock Options | N/A | 2,189,836 options | Weighted average exercise price $1.74 | Active employee and director option pool. |
Total warrant overhang stands at 15,199,384 shares with a weighted average exercise price of $0.51 per share, representing 77.4% of pre-offering common stock.
The active debt portfolio totals $2.1 million as of July 31, 2026, comprising short-term, high-cost debt instruments featuring Original Issue Discount (OID) structures and weekly/monthly amortization schedules.
Table Outstanding Debt Obligations and Convertible Financing Structure
| Debt Instrument & Lender | Outstanding Principal ($) | Interest Rate / OID | Repayment Terms & Amortization Schedule | Collateral / Default Conversion Terms |
| Agile Lending Loan (July 2026) | 825,000 | $363,000 total interest | 30 weekly cash payments of
148,500/mo); matures March 3, 2027 |
First-lien security interest in all corporate assets; net proceeds were $254,350. |
| Vanquish Notes (Feb 2026) | 467,820 | $53,820 OID + 12% interest | $288,176 on Aug 15, 2026 + 6 monthly of $39,297; matures Feb 15, 2027 | Default conversion at 25% discount to 10-day lowest trading price. |
| June 2026 OID Notes | 500,000 | $100,000 OID | Issued for gross proceeds of $400,000; short-term maturity | Unsecured promissory notes. |
| Unsecured Bridge Note | 125,000 | $75,000 original OID | Extended maturity to May 15, 2026; $375,000 original principal | Default conversion at 50% 5-day VWAP (80% floor of Nasdaq Minimum Price). |
| Mast Hill Convertible Note | 0 (Settled) | Reset to $1.00 floor | Final $545,950 converted Jan 2026 into 545,950 common shares | Original $2,845,000 note; forced $9,076,587 loss on debt extinguishment in FY25. |
Supply Chain Footprint, Contractual Exposure, and Legal Liabilities
Change Agents Corporation maintains its principal executive headquarters at 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728. The building was previously owned by subsidiary Avalon RT 9 Properties LLC, which generated rental revenues of $1,410,259 in FY 2025 ($1,333,403 in FY 2024) at a 98.5% occupancy rate. On February 18, 2026, Change Agents Corporation sold 100% of Avalon RT 9 to Chairman Wenzhao "Daniel" Lu for $9,000,000 (satisfying $3,158,078 in historical cash advances and assuming $5,900,000 in mortgage debt, exceeding a CBRE appraisal of $8,700,000). The transaction generated a net deconsolidation gain of $1,861,266, which was credited directly to Additional Paid-in Capital (APIC) under SEC related-party rules rather than recognized as income. Change Agents Corporation subsequently leased back its headquarters office space from Mr. Lu.
Total undiscounted operating lease liabilities stand at $178,500 ($97,000 due twelve months ending March 31, 2027; $70,500 due twelve months ending March 31, 2028; $11,000 due twelve months ending March 31, 2029). Discounted present value is $160,345 utilizing a 12.0% discount rate ($83,508 current portion; $76,837 non-current portion).
The consumer health technology segment (Keto Air breathalyzer measuring breath acetone PPM across tiers: 0–3.99 Inadequate, 4–9.99 Mild, 10–40 Optimal, >40 Alarming) operates via an exclusive North American distribution contract with Qi Diagnostics executed in 2024. Formal contractual exclusivity expired in July 2025, though Change Agents Corporation remains the sole distributor in North America. The segment owns zero manufacturing facilities and relies on a single Hong Kong technology group to produce all device hardware. Inventory of Keto Air finished goods was $71,862 as of March 31, 2026 ($74,841 as of December 31, 2025). Commercial distribution uses direct website channels, influencer partnerships, and a wellness contract with the Law Enforcement Association of America (LEAA). Development of a companion THC breathalyzer was permanently discontinued in March 2026 due to lack of capital.
The software segment (Avalon Quantum AI LLC) operates the Catch-Up short-form video platform and The Beacon Agentic GEO search app. Catch-Up Phase 1 targeted podcasters; Phase 2 (scheduled launch Q3 2026) expands to social media influencers, product marketers, and e-commerce. On March 31, 2026, the company engaged Caylent, Inc. (an AWS Premier Tier Consulting Partner) to build and manage its cloud backend on Amazon Web Services (AWS). Change Agents Corporation capitalized $18,037 in internal-use software development costs during Q1 2026 under ASC 350-40. On August 4, 2026, the company announced the formation of Autonomous Air Defense Systems LLC, a wholly-owned subsidiary tasked with developing generative AI models for counter-unmanned aerial systems (C-UAS) and autonomous drone surveillance, appointing Major General (Ret.) Malcolm Frost to its advisory board.
Active operations in China (Avalon Shanghai) were wound down between 2022 and 2023. Chinese cash balances were liquidated to $78 (0.01% of total cash) as of March 31, 2026 ($492 as of December 31, 2025). Foreign currency translation loss in OCI was $9,402 in FY 2025. Legacy cellular therapy patents co-owned with the Massachusetts Institute of Technology (MIT) require MIT's express consent for unilateral licensing or enforcement. Three provisional patent applications have been filed for the Catch-Up platform.
Legal and non-operating liabilities include:
* Nationwide Children's Hospital Settlement: Lawsuit filed October 28, 2019, alleging trade secret misappropriation against Change Agents Corporation and subsidiary Genexosome. Settled June 7, 2022, for $450,000 paid on 60-day, 1-year, and 2-year anniversaries ($363,450 accrued balance remaining as of March 31, 2026). Enforces a profit-sharing liability equal to 30% of the first $3,333,333 in pre-tax profits, 20% of the second $3,333,333, and 10% of the third $3,333,333 (up to $2,000,000 cumulative cash drag from first $10.0M pre-tax profit).
* Laboratory Services MSO, LLC Litigation: Lawsuit filed July 22, 2025, in DE Court of Chancery; settled August 26, 2025, for $1,722,000 ($50,000 legal fees, $22,000 interest). A $1,650,000 write-off taken in Q2 2025 was reinstated in Q3 2025. Following a $600,000 initial payment in August 2025, the remaining $1,122,000 balance is payable in 12 monthly cash installments of $93,500 through August 2026.
* IRS Section 6038 Tax Penalty: $10,000 penalty assessed for failure to file foreign entity tax disclosures (under active appeal).
* Hudson ELOC Warrant Buyout Obligation: Stockholder approval for shares underlying the Hudson Warrant must be obtained within 75 calendar days of July 22, 2026; failure allows Hudson to demand a $250,000 cash buyout to extinguish the warrant. Contract carries open-market "Buy-In" cover liabilities for delayed share delivery.
* Beijing Genexosome Liability: $100,000 in unpaid acquisition consideration from 2017 remains due to related party Dr. Yu Zhou (former director and 40% owner of Genexosome).
* Nasdaq Exchange Deficiency: Written notice received April 15, 2026 under Listing Rule 5550(a)(2) for closing below $1.00 for 30 consecutive business days. Compliance grace period runs through October 12, 2026.
The corporate governance framework features a 4-member Board of Directors (3 independent under Nasdaq rules following the simultaneous resignations of William Stilley, Wilbert Tauzin, and Tevi Troy on February 24, 2026). The board comprises Wenzhao "Daniel" Lu (Chairman, non-independent), Steven A. Sanders (Lead Independent Director, Of Counsel Ortoli Rosenstadt LLP), Lourdes Felix (Audit Chair, CEO/CFO BioCorRx Inc.), and Michael Mathews (Compensation Chair, former CEO Interclick). The executive officer suite consists of Meng Li (Interim CEO & COO), Sam Knipper (CFO, SEC Reporting Manager at Brio Financial Group, appointed June 3, 2026), Luisa Ingargiola (CSO, former CFO), and Michael Mathews (CEO of Avalon Quantum AI LLC). The company operates without a Chief Technology Officer (CTO). Total headcount as of July 31, 2026, is 3 full-time employees and 5 sub-contractors (8 total personnel).
Luisa Ingargiola’s Executive Retention Agreement dated June 3, 2026, sets base salary at $230,000, up to a 100% annual bonus ($230,000), a $230,000 cash bonus upon stockholder approval of the Series E conversion, a $230,000 change-of-control cash bonus, and 12 months salary severance ($230,000) plus option acceleration. Ms. Ingargiola received a $175,000 cash bonus in FY 2025 alongside a $350,000 base salary. Meng Li’s COO contract enforces a 12-month base salary severance clause ($340,000 historical rate). Equity incentive plans include the 2026 Omnibus Plan (2,000,000 shares reserved; 1,200,000 ISO cap), the 2020 Plan (175,537 shares available/outstanding), and the 2019 Plan (6,213 shares available).
Table Insider Ownership and Significant Shareholder Position Analysis
| Insider / 5% Blockholder | Common Shares Held | Voting Power (% Pre-Offering) | Preferred Stock Holdings | Notes & Options |
| Wenzhao "Daniel" Lu (Chairman) | 2,513,617 | 17.10% | Exchanged 5,000 Series D | Includes 17,642 shares via WLM Limited. |
| Meng Li (Interim CEO/COO) | 436,334 | 2.90% | None | Includes 402,000 active stock options. |
| Luisa Ingargiola (CSO) | 416,000 | 2.80% | None | Consists entirely of 416,000 stock options. |
| All Officers & Directors (7 persons) | 4,006,953 | 25.22% | Hold Series E via Mathews | Combined insider voting block. |
| Armistice Capital Master Fund Ltd. | 1,125,000 | 5.42% | None | Shares underlying pre-funded warrants. |
| Platinum Edge Limited | 1,031,865 | 4.99% | 2,550 Series C Preferred | Shares underlying Series C conversion. |
| Darin Myman (Myseum, Inc.) | 347,340 | 2.37% | 7,090.57 Series E Preferred | Excludes 4,727,046 shares due to Nasdaq cap. |
| Allen E. Cage | 800,000 | 3.91% | 400 Series F Preferred | Shares underlying Series F conversion. |
Related-party payments include $385,627 paid cumulatively from 2022 through Q1 2026 ($15,000 Q1 2026; $15,597 Q1 2025; $60,794 FY 2025; $63,644 FY 2024; $446,558 through August 2026) to former director Wilbert Tauzin and his son for consulting services. Chairman Lu previously provided a $20.0 million unsecured credit line at 5% interest (matured December 31, 2024; $42,445 interest paid in FY 2024).
M&K CPAS, PLLC issued an unqualified audit opinion for FY 2025 and FY 2024 with a going concern explanatory paragraph, disclaimed an opinion on Internal Control over Financial Reporting (ICFR), and identified the valuation of Goodwill ($12,808,197) and Intangibles ($2,252,000) from the RPM acquisition as a Critical Audit Matter (CAM). Recent accounting standard adoptions include ASU 2020-06, ASU 2023-07, and ASU 2023-09, while ASU 2024-03/2025-01, ASU 2025-06, ASU 2025-11, and ASU 2025-12 remain under evaluation.
HDIN Institutional Research Verdict
The registered S-1 resale offering functions as a liquidity preservation structure rather than an expansion capital raise. Change Agents Corporation receives $0 in direct proceeds from secondary resales, relying on Hudson Global Ventures drawing down up to $10.0 million under the ELOC at a fixed price of $0.30 per share. Fully drawing the line requires issuing 33,333,333 common shares, expanding the outstanding common stock base from 19,646,803 to 52,980,136 shares (a 169.6% dilution). If all registered resale shares (35,569,258) are issued, common shares reach 53,906,061 (an 181.0% dilution).
The cash flow absorption of existing obligations will consume available capital. Servicing the Agile Lending loan ($148,500 monthly amortization), executing Series F mandatory redemptions ($125,000 monthly starting October 2026), and clearing $2,025,508 in accrued professional and payroll liabilities requires $2,846,508 over the next four months—exceeding the company's $200,000 cash balance and available operating cash flows.
ELOC draws require the stock price to remain above $0.41 per share on the two trading days prior to a Put Date to trigger even the minimum $15,000 draw. With the stock trading below the Nasdaq $1.00 minimum bid threshold (under active deficiency notice through October 12, 2026), continuous market dumping of registered resale shares by Hudson risks driving the market price below the $0.41 floor, which would freeze access to the ELOC and accelerate insolvency.
Presentation Download & Video Access:
- Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
- Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer:
"This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards."